A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
Part of paid clinical trials in Mobile, Alabama.
- Sponsor
- Bristol-Myers Squibb
- Study ID
- NCT04100018
- Phase
- PHASE3
- Status
- Completed
Conditions
Eligibility Criteria
- Sex
- MALE
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- Nivolumab — BIOLOGICALSpecified dose on specified days
- Prednisone — DRUGSpecified dose on specified days
- Docetaxel — DRUGSpecified dose on specified days
- Placebo — OTHERSpecified dose on specified days
Study Details
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Key Dates
- Start date
- Feb 6, 2020
- Status verified
- May 2025
- Primary completion
- Jun 1, 2023
- Completion
- Jun 25, 2024
Study Design
- Enrollment
- 1,030 participants (actual)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Experimental: Arm A: Nivolumab + docetaxel + prednisone
- Placebo Comparator: Arm B: Placebo + docetaxel + prednisone
Primary Outcome Measure
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3) [ Time Frame: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months) ]
Locations (45)
Find similar trials in Mobile, AL
By condition
By specialty
Related Studies
- Collection of Blood From Patients With CancerRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- Use of Tracking Devices to Locate Abnormalities During Invasive ProceduresEnrolling By Invitation · National Institutes of Health Clinical Center (CC) · Bethesda, Maryland
- Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer StudiesRecruiting · National Cancer Institute (NCI) · Bethesda, Maryland
- [18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate CancerRecruiting · Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey